Today, the subscription period begins in SynAct Pharma’s rights issue, which will primarily finance further clinical phase II development with AP1189 in rheumatoid arthritis. CEO Jeppe Øvlesen visited BioStock Studio to talk about why AP1189 stands out among other treatments for inflammatory and autoimmune diseases, and why the rights issue is being carried out at right now. We also get insights from SynAct Pharma’s discussions with potential partners and how they leverage the feedback they receive from these talks.
Watch the full interview with SynAct Pharma’s CEO Jeppe Øvlesen below.
Read more in BioStock’s article SynAct Pharma well positioned for an eventful 2022.The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.